sur Immunic AG
Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Immunic, Inc. (Nasdaq: IMUX), a biotechnology firm focusing on oral therapies for chronic inflammatory and autoimmune diseases, announced its Q2 2024 financial results and corporate updates. Jason Tardio, an expert in multiple sclerosis drug commercialization, has joined as Chief Operating Officer and President. Additionally, Simona Skerjanec was appointed to the Board of Directors.
The company’s Phase 3 ENSURE trials and Phase 2 CALLIPER trial in multiple sclerosis are on schedule. Immunic plans to reveal more about its MS development program during the MS R&D Day in New York in September.
Financial highlights showed a reduction in research and development expenses compared to the previous year. Cash and cash equivalents amounted to $79.7 million as of June 30, 2024, enabling operations funding into Q3 2025.
The net loss for Q2 2024 was approximately $21.4 million, with the company planning a webcast to discuss results in detail.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Immunic AG